Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.

Laura LucaroniTony GeorgievEleonora ProdiSara PuglioliChristian PellegrinoNicholas FavalliLuca PratiMarkus G ManzSamuele CazzamalliDario NeriSebastian OehlerGabriele Bassi

Published in: European journal of nuclear medicine and molecular imaging (2022)

We conclude that the membranous expression of GCPIII in kidney and salivary gland may be the underlying cause for unwanted accumulation of Pluvicto™ and other Glu-ureido PSMA radio pharmaceuticals in patients.

Keyphrases

small molecule
pet ct
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
poor prognosis
prognostic factors
computed tomography
cancer therapy
patient reported outcomes